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ABSTRACT
Introduction: Activating mutations of K-Ras gene have a well-established role as 
predictors of resistance to anti-EGFR monoclonal antibodies in metastatic colorectal 
cancer (mCRC) patients. Their prognostic value is controversial, and no data regarding 
the prognostic value of mutation rate, defined as the percentage of mutated alleles/
tumor sample, are available. We aimed to evaluate the prognostic value of K-Ras 
mutation rate in a homogenous cohort of mCRC patients receiving first-line doublet 
plus bevacizumab. 
Patients and Methods: This retrospective study enrolled 397 K-Ras mutant mCRC 
patients from 6 Italian centers, and 263 patients were fully evaluable for our analysis. 
K-Ras mutation rate was assessed by pyrosequencing. Patients with less than 60% of 
cancer cells in tumor tissue were excluded. No patients received anti-EGFR containing 
anticancer therapy, at any time. Median mutation rate was 40% and was adopted as 
cut-off. The primary and secondary endpoints were PFS and OS respectively.
Results: At univariate analysis, K-Ras mutation rate higher than 40% was 
significantly associated with lower PFS (7.3 vs 9.1 months; P < 0.0001) and OS 
(21 vs 31 months; P = 0.004). A multivariate model adjusted for age at diagnosis, 
site of origin of tumor tissue (primary vs metastases), referral center, number of 
metastatic sites, and first-line chemotherapy backbone, showed that K-Ras mutation 
rate remained a significant predictor of PFS and OS in the whole population. 
Discussion: Our data demonstrate an association between K-Ras mutation 
rate and prognosis in mCRC patients treated with bevacizumab-containing first-line 
therapy. These data deserve to be verified in an independent validation set.
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INTRODUCTION
The Kirsten Rat Sarcoma (K-Ras) oncogene 
encodes for a 189 amino acids protein, also called p21, 
a member of RAS superfamily proteins [1]. Mutations in 
K-Ras gene are found in approximately 30% of all human 
cancers [2] and in 35-45% of colorectal cancers (CRCs) 
[3-5]. The 95% of K-Ras mutations occurs in codons 12 
and 13 while mutations in codons 61, 146 and other are 
less frequent in CRC, accounting for 5% of all mutations 
[6]. Activating mutations of the K-Ras oncogene is an 
established predictive biomarker for resistance to anti-
epidermal growth factor receptor (anti-EGFR) therapies 
in metastatic CRC (mCRC). Even though selection of Ras 
wild type (i.e. K-Ras and N-Ras exons 2, 3 and 4) greatly 
improve efficacy of EGFR-targeted agents by excluding 
50% to 60% of patients with tumors refractory to EGFR 
blockade [7-8], molecular alterations in additional nodes 
of the EGFR signalling network also seem to be clinically 
relevant. Among these, downstream mutations such as in 
B-Raf and PIK3CA genes have been investigated through 
several sequencing methods [9-11].
Despite of the well known importance of K-Ras 
mutations as predictive factor to anti-EGFR drugs 
administration, there is no consensus about the prognostic 
value of mutational status of K-Ras in CRC patients. 
Several reports have indicated that K-Ras mutations 
are negative prognostic markers and portend a poorer 
outcome in CRC [12] and a meta-analysis of 3439 
patients reported that mutation on codon 12 glycine to 
valine has a statistically significant impact on failure-
free survival (FFS) (P = 0.004, HR:1.3) and overall 
survival (OS) (P = 0.008, HR:1.29) and it is associated 
with a more aggressive biological behaviour of tumor 
[13]. A retrospective analysis of FOCUS trial showed 
that activating mutation in K-Ras and B-Raf oncogene 
are associated with shorter survival: patients harbouring 
K-Ras mutation have worse OS than patients with K-Ras 
wt tumors (HR:1.24; 95%CI:1,06-1.46; P = 0.008), but 
there is no evidence of an effect on progression free 
survival (PFS) (HR:1.14; 95%CI:0,98-1.33; P = 0.09) 
[14]. A recent post hoc analysis of the TRIBE study 
confirmed the negative prognostic role of K-Ras mutation 
in patients with mCRC treated with bevacizumab; more 
in details: the OS of all wt Ras patients was 34.4 months 
and 41.7 months when they received bevacizumab and 
FOLFIRI or bevacizumab and FOLFOXIRI respectively 
(HR: 0.84, 95%CI: 0.51-1.38), while the OS of mutant 
Ras patients was 23.1 months and 28.6 months when they 
received bevacizumab and FOLFIRI or bevacizumab 
and FOLFOXIRI [15] respectively (HR: 0.86, 95%CI: 
0.61 to 1.23). The PFS of all Ras wt patients was 11.3 
months vs 13.3 months in Ras mutant patients treated 
with bevacizumab and FOLFIRI or bevacizumab and 
FOLFOXIRI.
Up to now different methods for K-Ras mutation 
analysis have been used in experimental settings or in 
clinical trials in order to transfer useful predictive and 
prognostic information to clinical practice. Currently, the 
use of more sensitive methods has significantly improved 
the detection of K-Ras mutations. Interestingly while 
K-Ras mutation status has been always considered a 
dichotomic information, the recently use of technologies 
such as pyrosequincing, allow to identify an additional 
parameter i.e. the mutation rate, that is a measure of the 
rate of mutant alleles. The introduction and understanding 
of the biological significance and potential clinical impact 
of this new parameter could represent a high priority for 
patients evaluation. Indeed to our knowledge, there are 
no data about prognostic and\or predictive significance 
of rate of mutation of K-Ras in tumor specimens of 
mCRC patients treated with bevacizumab-containing 
chemotherapy in order to identify a specific subgroup of 
mutant K-Ras patients receiving a significant prognostic 
benefit from adding bevacizumab. We aimed to evaluate 
the correlation between rate of mutation of K-Ras and 
response to bevacizumab-containing treatment as well as 
its prognostic effect. 
RESULTS
Patients’ population
In this study we recruited 397 patients; 92 patients 
were excluded because of insufficient percentage of tumor 
cells in tissue samples (< 60%) and other 42 patients 
because of incomplete follow up or other missing data. 
We totally analyzed a population of 263 patients, 144 
(54.6%) male and 119 (43.4%) female. The Figure 1 
provides an overview diagram indicating the number of 
patients enrolled and analyzed in this study (Figure 1). 
K-Ras determination was performed on primary tumors 
for 69 (26.2%) patients and on metastatic cancer sites for 
194 (73.8%). The results showed that mutant codon 12 
was present in 211 (80%) patients, mutant codon 13 in 
44 (17%) patients, while other rare mutations of K-Ras 
were present in 8 (3%) patients. All enrolled subjects 
have available data about bevacizumab-chemotherapy 
regimens, in particular all patients received bevacizumab; 
201 (76.4%) patients received a first-line containing 
irinotecan, while 62 (23.6%) an oxaliplatin containing 
schedule. Among the whole population 191 (72.6%) 
of patients experienced a second-line therapy and 122 
(46.4%) a third line. The majority of patients who showed 
one organ compromised were 178 (67.7%), multi-organ 
involvement refer to 49 (18.6%) patients with two organs 
implicated, while 36 (13.7%) subjects presented 3 or more 
interested organs. Objective tumor response (achieved 
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Table 1: Patients’ features.
Absolute number %
Number of evaluable patients 263 100
Available data about Bevacizumab-chemotherapy 263 100
Gender (male/ female) 144/119 54.6/43.4
K-Ras determination (primary vs met) 194/69 73.8/26.2
Second Line 191 72.6
Third Line 122 46.4
Irinotecan based/ Oxaliplatin based 201/62 76.4/23.6










Cumulative response rate (cPR+cCR) 49% -
PFS 8.25 months 7.6-8.9
OS 26 months 22-29.9 
Figure 1: Diagram of the patients’ cohort enrolled in the study.
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as a confirmed PR or CR) was observed in 49% of the 
whole population. The median PFS and OS of mutant 
K-Ras patients were 8.25 months (95%CI: 7.6-8.9) and 26 
months (95%CI: 22.03-29.97) respectively. Characteristics 
of evaluable patients were summarised in Table 1. 
Prognostic value of mutant K-Ras alleles: 
univariate analysis
In order to investigate the prognostic value of K-Ras 
mutation rate we firstly performed a survival analysis for 
the calculation of PFS and OS. We divided subjects into 
three groups: those mutated in codon 12, 13 and those 
with mutation on K-Ras rare codons. Each group was then 
dichotomized for the presence of a mutation rate higher or 
lower than 40%; the total number of the analyzed patients 
with a mutation rate > 40% was 109, while that of patients 
with a mutation rate < 40% was 154. The survival data 
were then used for the univariate analysis using the log 
rank test. We obtain that higher mutation rate resulted in 
a poor outcome in terms of PFS and OS. In particular the 
median PFS for mutant K-Ras patients was 8.25 months 
(95%CI: 7.48-9.01), but the PFS in mutant codon 12 
patients with < 40% of mutation rate was 9.45 months 
(95%CI: 8.47-10.42) and that with ≥ 40% was 7.5 months 
(95%CI: 5.78-9.21). The median PFS in mutant codon 13 
K-Ras patients was 8.9 months (95%CI: 7.69-10.10), the 
median PFS in mutant codon 13 K-Ras patients with < 
40% and ≥ 40% was 10.25 months (95%CI: 8.15-12.34) 
and 7.25 months (95%CI: 14.40-43.59) respectively. The 
median PFS for other K-Ras mutations was 5.5 months 
(95%CI: 2.95-8.04), while the PFS for < 40% and ≥ 40% 
patients was 7.25 months (95%CI: 2.44-12.05) and 5.5 








all patients (pts) 8.25 (95%CI: 7.48-9.01) 28 (95%CI: 23.67-32.32)
Codon 12,  
pts with >40% vs ≤40% mutant alleles
7.45 (95%CI: 5.78-9.21) vs   9.45 (95%CI: 
8.47-10.4)
23 (95%CI: 19.79-26.20) vs 31 
(95%CI: 27.00-34.99)
Codon 13, 
all pts 8.90 (95%CI: 7.69-10.10) 21 (95%CI: 16.63-25.36)
Codon 13, 
pts with >40% vs ≤40% mutant alleles
  7.25 (95%CI: 3.6-10.89) vs 10.25 (95%CI: 
8.15-12.32)
17 (95%CI: 11.61- 22.78)  vs 24 
(95%CI: 19.41- 28.58)
Rare codons, 
all pts 5.50 (95%CI: 2.95- 8.04) 31 (95%CI: 27.03-34.03)
Rare codons, 
pts with >40% vs ≤40% mutant alleles
5.5 (95%CI: 10.75-31.04) vs 
7.25 (95%CI: 2.44-12.05)                       -
All K- Ras mutated codons, 
pts with >40% vs ≤40% mutant alleles
7.25 (95%CI: 5.76 -8.73) vs   9 (95%CI: 
7.96-10.03)
21 (95%CI: 18.35-23.64) vs 
31 (95%CI: 26.66-35.33)
Log-Rank P P=0.000 P=0.002
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months (95%CI: 2.68-7.76) in that order. Regarding the 
median survival, OS of mutant K-Ras patients treated 
with a first line bevacizumab-containing treatment was 26 
months (95%CI: 22.03-29.97). The median OS of mutant 
codon 12 patients was 28 months (95%CI: 23.67-32.32), 
but the OS in mutant codon 12 patients with < 40% was 
31 months (95%CI: 27.00-34.99), while the OS in mCRC 
patients with codon 12 K-Ras mutation ≥ 40% was 23 
months (95%CI: 19.79-26.20). The median OS in mutant 
codon 13 patients was 21 months (95%CI: 16.63-25.36); 
the OS in mutant codon 13 K-Ras patients with < 40% 
and ≥ 40% was 24 months (95%CI: 19.41-28.58) and 17 
months (95%CI: 11.61-22.78) respectively. The OS of 
other rare mutant codons K-Ras patients was 31 months. 
In the univariate survival analysis, the patients with a 
mutation rate higher than 40% was significantly associated 
with both PFS (log-rank P = 0.000) and OS (log-rank P 
= 0.002) with PFS and OS median value indicative of 
worse survival (median PFS: 7.25 months (95%CI: 5.76-
8.73) vs 9 months (95%CI: 7.96-10.03) and median OS: 
21 months (95%CI: 18.35-23.64) vs 31 months (95%CI: 
26.66-35.33)) correspondingly. The different subgroups 
survival data and Kaplan Meier curves are shown in Table 
2 and Figure 2.
A bioinformatic analysis was also conducted on a 
separate cohort consisting of 20 patients radically resected 
for liver metastasis and treated with chemotherapy. Taking 
advantage of the availability of primary and matched liver 
metastasis samples, we performed a correlation analysis 
finding a positive association (P = 0.030) between K-Ras 
mutation rate on the two sites. A subsequent Kaplan 
Meier survival analysis did not find any ability of K-Ras 
mutation allele frequency in predicting OS (P = 0.88), 
but we found that the cut-off (35%) generated through 
ROC method was very close to the one (40%) we used to 
dichotomize our cohort.
Prognostic value of mutant K-Ras alleles: 
multivariate analysis
Since we have shown that the presence of more than 
40% of mutation rate were associated with worse PFS 
and OS, we also applied a Cox’s regression model with 
these factors included in order to estimate the independent 
effect of the mutation rate on the two outcomes. This 
unadjusted analysis provide the following results: for 
PFS an HR = 0.63 (95%CI: 0.46-0.80) with a P < 0.001, 
and for OS an HR = 0.66 (95%CI: 0.44-0.84) with a P 
= 0.004. Moreover the multivariate Cox proportional 
hazards analysis, performed to compare prognostic 
factors of survival after adjustment for the impact of other 
factors (age at diagnosis, tumor tissue used for molecular 
analysis, reference center, number of metastatic sites, first-
line chemotherapy) displayed a significative association 
between mutation rate and the two outcome’ predictors 
(for PFS: HR: 0.67, 95%CI: 0.53-0.82, P = 0.003; for 
OS: HR: 0.67, 95%CI: 0.53-0.82, P = 0.003). Finally, we 
investigate the independent effect of mutation rate (more 
or less than 40% mutant alleles) of codons 12, 13 and rare 
codons introducing them into the multivariate analysis; 
among these only codon’ 12 mutation rate present a 
significant association with PFS (HR: 0.71, 95%CI: 0.52-
0.85, P = 0.003) and OS (HR: 0.71, 95%CI: 0.52-0.85, P 
= 0.003). 
Overall, these results demonstrated that K-Ras 
alleles mutation rate remained a significant predictor of 
PFS and OS (codon 13 and rare codons did not reach 
statistical significance probably due to the low number of 
patients) (Table 3).
DISCUSSION
In the era of personalized medicine, the improved 
understanding of the EGFR pathway clarified that 
mutations of Ras genes are established negative predictive 
factors with regard to the use of anti-EGFR monoclonal 
antibodies. Not only the negative predictive value of 
K-Ras exon 2 mutations was validated in a number of 
studies [3, 5], but also the analysis of other mutations 
such as codon 61 in exon 3 and codon 146 in exon 4 may 
predict resistance to these drugs [16]. Moreover, since 
tumors harbouring any Ras mutation do not respond 
to cetuximab or panitumumab [17], an expanded Ras 
analysis, including N-Ras exon 2, 3 and 4, has been 
Table 3: Multivariate Cox proportional hazards regression analysis. 
PFS OS
Survival Analysis (unadjusted) HR: 0.63 (0.46 -0.80)P < 0.001
HR: 0.66 (0.44-0.84)
P= 0.004
Survival Analysis (adjusted) HR: 0.67 (0.53-0.82)P= 0.003
HR: 0.71 (0.52-0.85)
P= 0.012
Codon 12 HR: 0.71 (0.52-0.85)P= 0.003
HR: 0.71 (0.52-0.85)
P= 0.011
Codon 13 HR: 0.62 (0.25-1.04)P= 0.066
HR: 0.579 (0.26-1.28)
P= 0.179




incorporated in the baseline evaluation of mCRC patients 
before treatment selection and the use of anti-EGFR 
monoclonal antibodies has been restricted to patients with 
Ras wild-type tumors.
Oppositely, the influence of K-Ras mutations on 
overall patients’ outcome is much less evident, indeed its 
prognostic value for patients with colorectal cancer is still 
debated. Even if K-Ras mutations seem not to correlate 
with the prognosis of patients with colorectal cancer the 
association remains to be confirmed with a more precise 
analysis of a large sample [18].
One of the reasons of these inconclusive results 
can be also attributed to cancer heterogeneity. Many 
tumors present heterogeneity within their cell population. 
This lack of cellular homogeneity may arise because 
of differential nutrient status due to an altered cancer 
induced microcirculations, normal cells’ infiltration into 
the tumor mass and to the hierarchical natures of the cell 
populations from which cancers arise. Recent findings 
demonstrated the complexity of settle and understand 
the heterogeneity of malignant disease, especially in 
an advanced setting. Some authors suggested that the 
molecular profile of the primary tumor might significantly 
differ from that of a corresponding metastatic site and 
might not reflect molecular aberrations accumulated as 
a consequence of selection pressure caused by applied 
cancer therapies. In addition, the molecular profile(s) of 
different metastatic sites might be disparate [19-21]. The 
molecular discordances between anatomic site locations 
of the same patient may hence reflect cancer heterogeneity 
[22]. Despite these data, other scientific reports established 
that, especially in patients never exposed to anti-EGFRs, 
the rate of concordance between primary tumor and 
corresponding metastatic sites is very high [23-25], and 
our data are in accordance with those findings. Moreover 
in the cancers’ genetic heterogeneity scenario is important 
to take into account that the percentage of K-Ras mutated 
cells into the tumor mass can vary from one patient to 
another and this fact may substantially influence the ability 
to predict therapeutic response [26].
Our work includes a large, multi-institutional cohort, 
involving 263 real-world patients and aims to define the 
prognostic value of K-Ras mutation rate in a homogeneous 
population of patient treated with a first-line containing 
bevacizumab. We decided to consider PFS as the primary 
endpoint of the study because of its shorter available 
follow-up time and its independence from additional 
subsequent therapies, which preserved the homogeneity 
of our patients’ population. Furthermore, some correlation 
analysis showed associations between PFS and OS in 
some cancers such as mCRC [27]. 
We should also admit some limits; first of all the 
greatest bias of our work derives from the retrospective 
nature of the study itself. We decided to exclude from 
the analysis 92 patients because insufficient percentage 
of tumor cells contained in their samples and other 42 
cases because of incomplete follow-up data: this caused a 
loss of 33% of the original cohort in the final analyses. In 
addition, the cut-off of 40% (median value) was arbitrarily 
chosen and not independently validated. Finally despite 
we used pyrosequencing to assess the mutational status 
of all patients, the analysis was performed in different 
laboratory. On the contrary the lack of detection of B-Raf 
and N-Ras mutations due to their mutually exclusive 
nature do not represent a limit.
In the first prognostic analysis we confirm the 
Figure 2: Kaplan-Meier curves for PFS and OS.
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unfavorable K-Ras impact on both survival endpoints; 
interestingly these results were replicated when we 
investigated the effect of the mutation rate higher than 
40% (chosen as cut-off value) on PFS and OS (PFS; P 
= 0.000; OS; P = 0.002), independently of the type of 
mutation. This strong association emerged in each class 
of patients analyzed, grouped on the basis of the type 
of mutation (codon 12, 13 or rare codons), indeed PFS 
and OS was always higher (in terms of months) in those 
groups of patients with less than 40% of mutation rate, 
providing indication of a better survival.
These data encouraged us to apply a multivariate 
model for the evaluation of the independent effect of 
mutation rate of codons 12, 13 and rare codons. The 
analysis’ results showed that the prognostic value of exon 
2/3 K-Ras mutations is retained after correction for other 
well-known prognostic factors (age at diagnosis, tumor 
tissue used for molecular analysis, reference center, 
number of metastatic sites and first-line chemotherapy) 
and confirm the robustness of the mutation rate as an 
effective predictor of PFS and OS.
In conclusion our results demonstrate for the first 
time a correlation between the K-Ras mutation rate 
(presence of more or less than 40% mutant alleles) in 
a homogenous advanced CRC population treated with 
bevacizumab containing first-line regimens. Certainly, 
our data need to be confirmed in a validation prospective 




K-Ras mutation allele frequency was evaluated in 
Brannon et al cohort consisting of analyzed 69 patient trios 
of primary CRC, matched metastases and normal tissue 
retrieved from http://www.cbioportal.org/index.do using 
the following WEB API command http://www.cbioportal.
org/webservice.do?cmd=getMutationData&case_set_
id=coadread_mskcc_all&genetic_profile_id=gbm_tcga_
mutations&gene_list=KRAS. 20 Kras mutated patients 
treated with chemotherapy were selected for further 
analysis. Cut-off estimation for Kaplan Meier analysis 
for OS was performed through Receiving Operator Curve 
methods using Cutoff Finder (http://molpath.charite.de/
cutoff/).
Patients and clinical endpoints
This multicentric retrospective study enrolled 
397 consecutive patients from 6 Italian cancer centres 
with a histologically confirmed diagnosis of mutant 
K-Ras mCRC (evaluation performed homogeneously by 
pyrosequencing) and treated with first-line anticancer 
regimens containing bevacizumab. Two clinical endpoints 
were used: PFS was the time from start of treatment to 
first evidence of tumor progression or death; OS was the 
time from start of treatment to death from any cause. The 
study has been conducted in accordance with the ethical 
principles that have their origin in the current Declaration 
of Helsinki and it has been approved by the ethical 
committee of Campus Bio-Medico of Rome. This study 
satisfy the REMARK criteria [28].
Laboratory method
All tumor samples (belonging to primary tumor or 
metastatic lesions) used in this study were selected and 
dissected by an experienced pathologist, and were quality 
controlled by frozen section to ensure that tumor cells 
were present in at least 60% of the sample. FFPE sections 
were deparaffinised by submersion in xylene; the tissue 
was then incubated overnight at 56°C with Proteinase 
K (Qiagen, UK) to allow samples lysis and DNA was 
extracted using the Trizol reagent (Invitrogen, CA, USA) 
following the manufacturer’s instructions. To obtain RNA-
free genomic DNA, an RNase A (Qiagen, UK) treatment 
was performed following the protocol instructions. 
The concentration and purity of the isolated DNA were 
measured using a NanoDrop ND-1000 Spectrophotometer 
(Thermo Fisher Scientific, DE, USA). Pyrosequencing 
analysis was performed by each local laboratory with the 
exception of cases provide by ASB that were analysed 
by the coordinating centre. Pyrosequencing analysis of 
K-Ras status was carried out on 0.15-0.5 pmol of each 
PCR product using the PyroMark MD System (Qiagen) 
following the manufacturer’s instructions, with sequencing 
primers and assay parameters specific to each mutation. 
Codons 12, 13, 61, 117 and 146 of K-Ras gene were 
analysed. For each assay, pyrosequencing analysis was 
taken to represent the identified percentage burden of the 
mutant allele. The cut-off value, discriminating between 
the mutant and wild-type sequence, was arbitrarily 
assigned as 10% mutant allele burden. A score for each 
mutant sequence was used for statistical analysis; in 
particular we assigned score 0 whether mutant K-Ras 
alleles were present in less than 40% while score 1 whether 
mutant K-Ras alleles were present in at least 40%. The 
determination of 40% as cut off value of allelic frequency 
was established because it represented the median value of 
the percentage’ distribution of mutant alleles.
Statistical analysis
PFS was calculated as the period from the date 
of starting treatment to the first observation of disease 
progression or to death from any cause. The duration 
response was defined as the period of time from the 
Oncotarget31611www.impactjournals.com/oncotarget
initiation of treatment (in a patient responding to therapy) 
until documentation of radiological or symptomatic 
disease progression. The OS time was calculated as the 
period from the date of starting treatment until death 
from any cause or until the date of the last follow-up, at 
which point data were censored. PFS and OS were both 
determined by Kaplan-Meier product-limit method. 
Finally, the Cox proportional hazards model was applied 
to the multivariate survival analysis. Survival analysis 
in multivariate model was corrected for the following 
variables: age at diagnosis, tumor tissue used for molecular 
analysis, reference center, number of metastatic sites and 
chemotherapy regimen in first line. The cut-off point for 
survival data was May 2014. SPSS software (version 
17.00, SPSS, Chicago) was used for statistical analysis. 
A P value of less than 0.05 was considered to indicate 
statistical significance.
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